MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)
-- New investor Bpifrance leads Series B extension through the PSIM fund it manages on…
MaaT PharmaDecember 1, 2020
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe,…
MaaT PharmaNovember 25, 2020
MaaT033 is an oral formulation of MaaT Pharma’s full-ecosystem biotherapeutic characterized by high microbial diversity and richness Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy Lyon,…
MaaT PharmaNovember 12, 2020
-- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013,…
MaaT PharmaAugust 31, 2020
-- Data from the Company’s compassionate use program with MaaT013 as a treatment in patients…
MaaT PharmaAugust 28, 2020
La nouvelle campagne de collecte soutiendra le développement clinique futur du portefeuille de biothérapies à…
MaaT PharmaAugust 20, 2020
New collection campaign to support future clinical development of microbiome biotherapeutic product portfolio and to…
MaaT PharmaAugust 20, 2020
Lyon, France, July 16, 2020 – MaaT Pharma announced today the appointment of Claude Bertrand,…
MaaT PharmaJuly 16, 2020